Skip to main content
OpenTrials

Clinical trial condition

Breast Diseases

Explore clinical trials studying Breast Diseases. Study availability and eligibility vary by location and protocol.

10,339 public trials 1,980 recruiting studies
Refine in advanced search Browse all conditions

Breast Diseases trial results

Active, Not Recruiting

Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer

NCT03377387

Conditions
Breast Cancer, Breast Diseases, Breast Neoplasms, +4 more
Locations
  • Hartford Healthcare Cancer Institute @ Hartford Hospital Hartford, Connecticut, United States
  • Baptist Alliance - McI Miami, Florida, United States
  • Memorial Sloan Kettering at Basking Ridge Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth Middletown, New Jersey, United States
View Trial Details
Active, Not Recruiting

A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)

NCT03157128

Conditions
Adenocarcinoma, Adenocarcinoma, Papillary, Any Solid Tumor, +46 more
Locations
  • Mayo Clinic of Scottsdale Scottsdale, Arizona, United States
  • City of Hope National Medical Center Duarte, California, United States
  • UCLA Medical Center Los Angeles, California, United States
  • Hoag Memorial Hospital Presbyterian Newport Beach, California, United States
View all 85 locations
View Trial Details
Active, Not Recruiting

Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer

NCT06840483

Conditions
Breast Cancer, Breast Diseases, Breast Neoplasms, +4 more
Locations
  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (SKCCC) Baltimore, Maryland, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Siteman Cancer Center St Louis, Missouri, United States
  • Memorial Sloan Kettering Cancer Center - Main Campus New York, United States
View all 18 locations
View Trial Details
Active, Not Recruiting

Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression

NCT04920708

Conditions
Advanced Breast Cancer, Breast Diseases, Breast Neoplasms, +6 more
Locations
  • Addenbrookes Hospital Cambridge, Cambridgeshire, United Kingdom
  • Royal Cornwall Hospital Truro, Cornwall, United Kingdom
  • Mount Vernon Cancer Centre London, Surrey, United Kingdom
  • Velindre Cancer Centre Cardiff, Wales, United Kingdom
View all 13 locations
View Trial Details
Active, Not Recruiting

Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor

NCT04650581

Conditions
Breast Cancer, Breast Diseases, Breast Neoplasms, +4 more
Locations
  • Southern Highlands Cancer Centre Bowral, New South Wales, Australia
  • Lake Macquarie Private Hospital Gateshead, New South Wales, Australia
  • Gosford Hospital Gosford, New South Wales, Australia
  • Macquarie University Hospital Macquarie University, New South Wales, Australia
View all 39 locations
View Trial Details

Related conditions